DK3273995T3 - Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion - Google Patents
Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion Download PDFInfo
- Publication number
- DK3273995T3 DK3273995T3 DK16711320.8T DK16711320T DK3273995T3 DK 3273995 T3 DK3273995 T3 DK 3273995T3 DK 16711320 T DK16711320 T DK 16711320T DK 3273995 T3 DK3273995 T3 DK 3273995T3
- Authority
- DK
- Denmark
- Prior art keywords
- cftr
- alginatoligomers
- lumacaftor
- treatment
- conditions associated
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title 1
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 title 1
- 229960000998 lumacaftor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504878.8A GB201504878D0 (en) | 2015-03-23 | 2015-03-23 | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
| PCT/EP2016/056458 WO2016151051A1 (en) | 2015-03-23 | 2016-03-23 | Use of alginate oligomers and cftr modulators in the treatment of conditions associated with cftr dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3273995T3 true DK3273995T3 (da) | 2021-10-18 |
Family
ID=53052244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16711320.8T DK3273995T3 (da) | 2015-03-23 | 2016-03-23 | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10751363B2 (da) |
| EP (1) | EP3273995B1 (da) |
| AU (1) | AU2016236172B2 (da) |
| CA (1) | CA2980104A1 (da) |
| DK (1) | DK3273995T3 (da) |
| GB (1) | GB201504878D0 (da) |
| WO (1) | WO2016151051A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517639D0 (en) * | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
| FR3057011B1 (fr) * | 2016-10-03 | 2018-11-02 | S.P.C.M. Sa | Appareil de regulation de pression d'injection pour la recuperation assistee du petrole par polymere |
| CN106596488A (zh) * | 2016-12-14 | 2017-04-26 | 蔡璇 | 一种食品中磺胺残留量快速检测方法 |
| US11072668B2 (en) | 2017-01-03 | 2021-07-27 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
| CN110461338A (zh) | 2017-03-28 | 2019-11-15 | 北卡罗来纳大学查佩尔希尔分校 | 作为可生物降解抗菌支架的释放一氧化氮的聚氨基糖苷类和其制备方法 |
| CA3082130A1 (en) | 2017-11-15 | 2019-05-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto |
| CA3091458A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
| KR20200136430A (ko) * | 2018-03-19 | 2020-12-07 | 알지파마 에이에스 | 점액 층을 가로지르는 마이크로/나노입자의 전위를 향상시키기 위한 알지네이트 올리고머의 용도 |
| US11421044B2 (en) | 2018-12-28 | 2022-08-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
| CA3160752A1 (en) * | 2019-12-26 | 2021-07-01 | Preston E. BRATCHER | Methods of treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction |
| EP4277703A4 (en) * | 2021-01-15 | 2025-02-12 | Children's Hospital Medical Center | METHODS FOR OPTIMIZING CFTR MODULATOR THERAPY |
| US20230181610A1 (en) * | 2021-10-18 | 2023-06-15 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8805695D0 (en) | 1988-03-10 | 1988-04-07 | Nycomed As | Enteric coated spheroidal granules |
| AU7221691A (en) | 1990-01-23 | 1991-08-21 | Terje Espevik | Mannuronic acid containing alginate wound healing composition and method |
| US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
| GB9221163D0 (en) | 1992-10-08 | 1992-11-25 | Nobipol And Protan Biopolymer | Dna compounds |
| NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
| AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| NO326145B1 (no) | 2001-11-30 | 2008-10-06 | Fmc Biopolymer As | Fremgangsmate for a stimulere vektokning hos pattedyr, fugler og krypdyr. |
| NO20023581D0 (no) | 2002-07-26 | 2002-07-26 | Fmc Biopolymer As | Nye mutantstammer av Pseudomonas fluorescens og varianter derav, metoder for produksjon og bruk derav til produksjon avalginat |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PL2489659T3 (pl) | 2004-06-24 | 2018-06-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą atp |
| GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
| NZ567892A (en) | 2005-11-08 | 2010-12-24 | Vertex Pharma | Heterocyclic modulators of ATP-binding cassette transporters containing cycloalkyl or heterocycloalkyl groups |
| CA2652072A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| GB0707096D0 (en) * | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
| EP2222304A2 (en) | 2007-09-14 | 2010-09-01 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| PT2578571E (pt) | 2007-11-16 | 2015-11-30 | Vertex Pharma | Moduladores de transportadores de atp-binding cassette |
| CN104189908B (zh) * | 2007-11-27 | 2017-01-11 | 阿尔吉法玛公司 | 包含藻酸盐低聚物的产品、包含无生命表面的产品和清创组合物 |
| PL2225230T3 (pl) | 2007-12-07 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego |
| BRPI0820681A2 (pt) | 2007-12-07 | 2019-09-24 | Vertex Pharma | formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico |
| DK2639224T3 (da) | 2007-12-07 | 2016-10-17 | Vertex Pharma | Fremgangsmåde til fremstilling af cycloalkylcarboxiamido-pyridinbenzoesyrer |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| WO2010019239A2 (en) | 2008-08-13 | 2010-02-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
| EA018891B1 (ru) | 2008-10-23 | 2013-11-29 | Вертекс Фармасьютикалз, Инкорпорейтед | Модуляторы регулятора трансмембранной проводимости при муковисцидозе |
| BRPI0823228B8 (pt) | 2008-11-06 | 2021-05-25 | Vertex Pharmaceuticals Incorporarted | moduladores de cassete de ligação a atp |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| DK2437783T3 (da) | 2009-06-03 | 2014-01-20 | Algipharma As | Behandling af acinetobacter med alginatoligomerer og antibiotika |
| JP2013508414A (ja) | 2009-10-22 | 2013-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症および他の慢性疾患の治療のための組成物 |
| DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| CN105037334A (zh) | 2010-04-07 | 2015-11-11 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| CN105130948A (zh) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
| WO2011133953A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| EP2560649A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| CA2796646A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| EP2575814A1 (en) | 2010-05-20 | 2013-04-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US20120064157A1 (en) | 2010-08-27 | 2012-03-15 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| KR20150000110A (ko) | 2013-06-24 | 2015-01-02 | 재단법인 전남생물산업진흥원 | 알긴산을 포함하는 천식 예방 또는 치료용 조성물 |
| JP2017510563A (ja) | 2014-02-28 | 2017-04-13 | アルギファルマ エーエス | 嚢胞性線維症及び欠陥ｃｆｔｒイオンチャネル機能に関連する他の病態の治療におけるアルギネートオリゴマーの使用 |
-
2015
- 2015-03-23 GB GBGB1504878.8A patent/GB201504878D0/en not_active Ceased
-
2016
- 2016-03-23 CA CA2980104A patent/CA2980104A1/en active Pending
- 2016-03-23 AU AU2016236172A patent/AU2016236172B2/en not_active Ceased
- 2016-03-23 WO PCT/EP2016/056458 patent/WO2016151051A1/en not_active Ceased
- 2016-03-23 EP EP16711320.8A patent/EP3273995B1/en active Active
- 2016-03-23 DK DK16711320.8T patent/DK3273995T3/da active
- 2016-03-23 US US15/560,984 patent/US10751363B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016151051A1 (en) | 2016-09-29 |
| GB201504878D0 (en) | 2015-05-06 |
| AU2016236172B2 (en) | 2021-07-01 |
| US10751363B2 (en) | 2020-08-25 |
| EP3273995A1 (en) | 2018-01-31 |
| US20180055873A1 (en) | 2018-03-01 |
| EP3273995B1 (en) | 2021-07-14 |
| CA2980104A1 (en) | 2016-09-29 |
| AU2016236172A1 (en) | 2017-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279752B (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| IL259441A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| IL257105A (en) | Modified cells and methods of therapy | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3325509T3 (da) | Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser | |
| DK3099717T3 (da) | Antistofmolekyler med tim-3 og anvendelser deraf | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3334422T3 (da) | Anvendelse af cannabidiolsyre i behandling af epilepsi | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| IL258259A (en) | Adjunctive therapy with 25-hydroxyvitamin d and articles therefor | |
| DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3619362T3 (da) | Forbedringer af og i forbindelse med barrierer | |
| DK3233066T3 (da) | Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser | |
| DK3439663T3 (da) | Fremgangsmåder til behandling af pædiatriske cancere | |
| DK3116897T3 (da) | Polymyxinderivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3576738T3 (da) | Gaboxadolmonohydrat i behandling af tinnitus | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3297651T3 (da) | Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf |